%0 Case Reports
%T 68Ga-pentixafor PET/CT in the localization diagnosis of primary aldosteronism concurrent subclinical cushing's syndrsome: two case reports.
%A Wei X
%A Wu F
%A Dong H
%A Jing Y
%A Song Y
%A Pang H
%A Chen J
%A Du Z
%A He W
%A Ma L
%A Wang Y
%A Hu J
%A Li Q
%A Yang S
%A  
%J Endocrine
%V 85
%N 3
%D 2024 Sep 24
%M 38914747
%F 3.925
%R 10.1007/s12020-024-03865-6
%X <B>OBJECTIVE: </B>Adrenal venous sampling (AVS) is recommended for subtyping primary aldosteronism (PA). However, in cases of PA, concurrent subclinical Cushing's syndrome (SCS) has the potential to confound AVS results. Pentixafor, a CXC chemokine receptor type 4-specific ligand, has been reported as a promising marker to evaluate functional nature of adrenal adenomas. This study aims to investigate the clinical value of Gallium-68 Pentixafor Positron Emission Tomography-Computed Tomography (68Ga-Pentixafor PET/CT) in the localization diagnosis of patients with PA plus SCS.<BR><B>METHODS: </B>Two patients with a confirmed diagnosis of PA plus SCS underwent AVS and 68Ga-Pentixafor PET/CT.<BR><B>RESULTS: </B>AVS results revealed no lateralization for both patients while 68Ga-Pentixafor PET/CT showed a unilateral adrenal nodule with increased uptake of 68Ga-Pentixafor. Unilateral adrenalectomy was performed based on the results of 68Ga-Pentixafor PET/CT. Subsequently, complete biochemical remission of autonomous aldosterone and cortisol secretion were achieved in both cases.<BR><B>CONCLUSIONS: </B>68Ga-Pentixafor PET/CT shows promising potential for the localization of aldosterone and cortisol co-secreting adrenal adenoma in patients with PA plus SCS.